Status:
COMPLETED
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborating Sponsors:
Case Western Reserve University
National Institute of Neurological Disorders and Stroke (NINDS)
Conditions:
Parkinson Disease
Parkinsonism
Eligibility:
All Genders
21-89 years
Brief Summary
The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate whether someone ...
Detailed Description
This is a clinical research study for patients with parkinsonism, including Parkinson's disease, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, and dementia with L...
Eligibility Criteria
Inclusion
- Age 21 years old and age \<90 years of age at the time of the baseline visit 1
- Age of diagnosis at least 40 years old for PD, DLB, and PSP and at least 30 years old for MSA
- A confirmed diagnosis of PD, PSP, CBD, MSA, DLB, or healthy control
- Montreal Cognitive Assessment (MoCA) \> 10 at the outset of the study
Exclusion
- Age 90 or above
- Allergy to local anesthetic
- History of deep brain stimulation (DBS) or other brain surgery prior to Visit 1
- For PD or DLB diagnoses, any other neurodegenerative or central nervous system process that would interfere with examination
- For PD or DLB, history of negative DATscan
- Use of investigational drugs or devices within 60 days prior to baseline visit (except for dietary supplements)
- In control subjects, family history of a neurodegenerative disease in a first degree or second degree blood relative
- History of schizophrenia
- History of antipsychotic medication use or exposure in controls or history of antipsychotic medication leading to parkinsonism (drug induced parkinsonism) in the parkinsonism group
- Blood clotting disorder
- On multiple (more than one) antiplatelet and/or anticoagulant blood thinner medications in combination (except for aspirin if it can be safely held for 1 week)
- Any other medical, psychiatric, or cognitive illness that in the investigator's opinion would interfere with cooperation or ability to undergo the study procedures.
Key Trial Info
Start Date :
March 12 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2025
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT04518059
Start Date
March 12 2019
End Date
May 31 2025
Last Update
July 1 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
2
University Hospitals Suburban Health Center
South Euclid, Ohio, United States, 44121